TP53 and prostate carcinoma: Therefore, TP53-4 (rs730882029) and TP53-6 (rs876659384), being stop-gained mutations, and TP53-5 (rs1131691022), being a frameshift mutation, show their potential as markers of TP53 inactivation in prostate cancer, showing potential for immunotherapy treatments.